Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193


One Screening for Ischemic Heart Disease, Lung Cancer, and Chronic Obstructive Pulmonary Disease: A Systems Biology Bridge for Tobacco and Radiation Exposure.

Mulshine JL.

Am J Public Health. 2018 Oct;108(10):1294-1295. doi: 10.2105/AJPH.2018.304655. No abstract available.


Status of lung cancer screening.

Mulshine JL.

J Thorac Dis. 2017 Nov;9(11):4311-4314. doi: 10.21037/jtd.2017.10.121. No abstract available.


Moonshot Acceleration Factor: Medical Imaging.

Sevick-Muraca EM, Frank RA, Giger ML, Mulshine JL.

Cancer Res. 2017 Nov 1;77(21):5717-5720. doi: 10.1158/0008-5472.CAN-17-1698. Epub 2017 Oct 9.


Quality assurance and quantitative imaging biomarkers in low-dose CT lung cancer screening.

Rydzak CE, Armato SG, Avila RS, Mulshine JL, Yankelevitz DF, Gierada DS.

Br J Radiol. 2018 Oct;91(1090):20170401. doi: 10.1259/bjr.20170401. Epub 2017 Oct 27. Review.


Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.


Implementing computed tomography-based lung cancer screening in the community.

Mulshine JL, Ambrose LF.

J Thorac Dis. 2016 Oct;8(10):E1304-E1306. No abstract available.


Lung cancer: current therapies and new targeted treatments.

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L.

Lancet. 2017 Jan 21;389(10066):299-311. doi: 10.1016/S0140-6736(16)30958-8. Epub 2016 Aug 27. Review.


Volumes Learned: It Takes More Than Size to "Size Up" Pulmonary Lesions.

Ma X, Siegelman J, Paik DS, Mulshine JL, St Pierre S, Buckler AJ.

Acad Radiol. 2016 Sep;23(9):1190-8. doi: 10.1016/j.acra.2016.04.003. Epub 2016 Jun 7. Review.


Lung cancer screening moving forward.

Rzyman W, Mulshine JL.

Ann Transl Med. 2016 Apr;4(8):149. doi: 10.21037/atm.2016.04.04. No abstract available.


Lung Cancer Workshop XI: Tobacco-Induced Disease: Advances in Policy, Early Detection and Management.

Mulshine JL, Avila R, Yankelevitz D, Baer TM, Estépar RS, Ambrose LF, Aldigé CR.

J Thorac Oncol. 2015 May;10(5):762-7. doi: 10.1097/JTO.0000000000000489.


Role of the Quantitative Imaging Biomarker Alliance in optimizing CT for the evaluation of lung cancer screen-detected nodules.

Mulshine JL, Gierada DS, Armato SG 3rd, Avila RS, Yankelevitz DF, Kazerooni EA, McNitt-Gray MF, Buckler AJ, Sullivan DC.

J Am Coll Radiol. 2015 Apr;12(4):390-5. doi: 10.1016/j.jacr.2014.12.003.


Lung cancer screening guidelines: common ground and differences.

Gulati S, Mulshine JL.

Transl Lung Cancer Res. 2014 Jun;3(3):131-8. doi: 10.3978/j.issn.2218-6751.2014.06.12. Review.


Shared decision making and screening: an ongoing dialogue informed by data.

Mulshine JL, Yankelevitz DF.

Oncology (Williston Park). 2015 Mar;29(3):149. No abstract available.


Lung cancer screening with low-dose CT: more questions than answers--author's reply.

Mulshine JL.

Lancet Oncol. 2015 Jan;16(1):e4. doi: 10.1016/S1470-2045(14)71163-5. Epub 2014 Dec 29. No abstract available.


Evaluation of an interactive science publishing tool: toward enabling three-dimensional analysis of medical images.

Rinewalt D, Williams BW, Reeves AP, Shah P, Hong E, Mulshine JL.

Acad Radiol. 2015 Mar;22(3):380-6. doi: 10.1016/j.acra.2014.09.012. Epub 2014 Dec 10.


Lung cancer screening: achieving more by intervening less.

Mulshine JL, Henschke CI.

Lancet Oncol. 2014 Nov;15(12):1284-5. doi: 10.1016/S1470-2045(14)70418-8. Epub 2014 Oct 1. No abstract available.


Issues with implementing a high-quality lung cancer screening program.

Mulshine JL, D'Amico TA.

CA Cancer J Clin. 2014 Sep-Oct;64(5):352-63. doi: 10.3322/caac.21239. Epub 2014 Jun 27. Review.


Tobacco control since the 1964 Surgeon General's Report: reflecting back and looking forward.

Mulshine JL, Healton C.

Oncology (Williston Park). 2014 Mar;28(3):180, 182-3, 210. No abstract available.


E-cigarettes and cancer patients.

Cummings KM, Dresler CM, Field JK, Fox J, Gritz ER, Hanna NH, Ikeda N, Jassem J, Mulshine JL, Peters MJ, Yamaguchi NH, Warren G, Zhou C.

J Thorac Oncol. 2014 Apr;9(4):438-41. doi: 10.1097/JTO.0000000000000129.


The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations.

Field JK, Aberle DR, Altorki N, Baldwin DR, Dresler C, Duffy SW, Goldstraw P, Hirsch FR, Pedersen JH, de Koning HJ, Mulshine JL, Sullivan DC, Tsao MS, Travis WD; International Association for the Study of Lung Cancer Strategic Screening Advisory Committee.

J Thorac Oncol. 2014 Feb;9(2):141-3. doi: 10.1097/JTO.0000000000000060. No abstract available.


Advancing patient-centric genomic medicine.

Mulshine JL.

Oncology (Williston Park). 2013 Sep;27(9):827. No abstract available.


Application of high-resolution CT imaging data to lung cancer drug development: measuring progress: workshop IX.

Mulshine JL, Avila R, Yankelevitz D, Baer TM, Estepar RS, Fenton L, Aldige CR.

J Thorac Oncol. 2013 Nov;8(11):1352-5. doi: 10.1097/01.JTO.0000435803.93490.04.


Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members.

Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, Dresler CA.

J Oncol Pract. 2013 Sep;9(5):258-62. doi: 10.1200/JOP.2013.001025. Epub 2013 Jul 29.


Lessons from considering the cancer landscape.

Mulshine JL.

Oncology (Williston Park). 2013 May;27(5):408, 410. No abstract available.


Not significant but important.

Mulshine JL, Ondrey FG.

Cancer Prev Res (Phila). 2013 May;6(5):371-4. doi: 10.1158/1940-6207.CAPR-13-0106.


The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups.

Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ.

J Thorac Cardiovasc Surg. 2012 Jul;144(1):33-8. doi: 10.1016/j.jtcvs.2012.05.060.


Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance.

Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Sugarbaker DJ, Swanson SJ, Travis WD, Jaklitsch MT.

J Thorac Cardiovasc Surg. 2012 Jul;144(1):25-32. doi: 10.1016/j.jtcvs.2012.05.059.


An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost.

Pyenson BS, Sander MS, Jiang Y, Kahn H, Mulshine JL.

Health Aff (Millwood). 2012 Apr;31(4):770-9. doi: 10.1377/hlthaff.2011.0814.


International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report.

Field JK, Smith RA, Aberle DR, Oudkerk M, Baldwin DR, Yankelevitz D, Pedersen JH, Swanson SJ, Travis WD, Wisbuba II, Noguchi M, Mulshine JL; IASLC CT Screening Workshop 2011 Participants.

J Thorac Oncol. 2012 Jan;7(1):10-9. doi: 10.1097/JTO.0b013e31823c58ab.


Lung cancer screening: what is the benefit and what do we do about it?

Mulshine JL, van Klaveren RJ.

Lung Cancer. 2011 Mar;71(3):247-8. doi: 10.1016/j.lungcan.2010.12.010. Epub 2011 Jan 31. No abstract available.


hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines.

Tauler J, Zudaire E, Liu H, Shih J, Mulshine JL.

Cancer Res. 2010 Sep 15;70(18):7137-47. doi: 10.1158/0008-5472.CAN-10-0860. Epub 2010 Aug 31.


Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer.

Chow G, Tauler J, Mulshine JL.

J Biomed Biotechnol. 2010;2010:485468. doi: 10.1155/2010/485468. Epub 2010 Jun 30.


Introduction: Imaging in diagnosis and treatment of lung cancer.

Mulshine JL, Baer TM, Avila RS.

Opt Express. 2010 Jul 5;18(14):15242-3. doi: 10.1364/OE.18.015242. No abstract available.


A quantitative method for estimating individual lung cancer risk.

Avila RS, Zulueta JJ, Shara NM, Jansen K, Veronesi G, Wang H, Mulshine JL.

Acad Radiol. 2010 Jul;17(7):830-40. doi: 10.1016/j.acra.2010.03.012.


An actuarial approach to comparing early stage and late stage lung cancer mortality and survival.

Goldberg SW, Mulshine JL, Hagstrom D, Pyenson BS.

Popul Health Manag. 2010 Feb;13(1):33-46. doi: 10.1089/pop.2009.0010.


The use of volumetric CT as an imaging biomarker in lung cancer.

Buckler AJ, Mulshine JL, Gottlieb R, Zhao B, Mozley PD, Schwartz L.

Acad Radiol. 2010 Jan;17(1):100-6. doi: 10.1016/j.acra.2009.07.030. Review.


Volume CT for diagnosis of nodules found in lung-cancer screening.

Mulshine JL, Jablons DM.

N Engl J Med. 2009 Dec 3;361(23):2281-2. doi: 10.1056/NEJMe0908771. No abstract available.


Lung cancer and inflammation: interaction of chemokines and hnRNPs.

Tauler J, Mulshine JL.

Curr Opin Pharmacol. 2009 Aug;9(4):384-8. doi: 10.1016/j.coph.2009.06.004. Epub 2009 Jun 29. Review.


Use of high-resolution CT imaging data in lung cancer drug development: measuring progress.

Mulshine JL, Avila R, Yankelevitz D, Baer TM.

Oncology (Williston Park). 2009 Apr 30;23(5):434-8. No abstract available.


Commentary: lung cancer screening--progress or peril.

Mulshine JL.

Oncologist. 2008 Apr;13(4):435-8. doi: 10.1634/theoncologist.2008-0068. No abstract available.


Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules.

Veronesi G, Bellomi M, Mulshine JL, Pelosi G, Scanagatta P, Paganelli G, Maisonneuve P, Preda L, Leo F, Bertolotti R, Solli P, Spaggiari L.

Lung Cancer. 2008 Sep;61(3):340-9. doi: 10.1016/j.lungcan.2008.01.001. Epub 2008 Mar 4.


Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Tauler J, Mulshine JL.

PPAR Res. 2008;2008:750238. doi: 10.1155/2008/750238. Epub 2009 Mar 4.


Biomedical imaging archive network.

Baer TM, Mulshine JL, Jacobs JJ.

Skeletal Radiol. 2007 Sep;36(9):799-801. No abstract available.


The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group.

Field JK, Smith RA, Duffy SW, Berg CD, van Klaveren R, Henschke CI, Carbone D, Postmus PE, Paci E, Hirsch FR, Mulshine JL.

J Thorac Oncol. 2006 Jun;1(5):497-8.


Early lung cancer detection: approaching the 'tipping point'?

Mulshine JL.

Oncology (Williston Park). 2006 Nov;20(12):1632. No abstract available.


Developing CT image-processing tools to accelerate progress in lung cancer drug development.

Mulshine JL, Avila RS, Hirsch FR, Yankelevitz D.

Oncology (Williston Park). 2006 Nov;20(12):1606, 1608-10, 1614 passim. Review. No abstract available.


Lung cancer screening.

Ganti AK, Mulshine JL.

Oncologist. 2006 May;11(5):481-7. Review.


Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886.

Mayburd AL, Martlínez A, Sackett D, Liu H, Shih J, Tauler J, Avis I, Mulshine JL.

Clin Cancer Res. 2006 Mar 15;12(6):1820-7.


Current issues in lung cancer screening.

Mulshine JL.

Oncology (Williston Park). 2005 Nov;19(13):1724-30; discussion 1730-1. Review.

Supplemental Content

Loading ...
Support Center